Cynthia Paredes-Paucar, Leonardo Villa Medina, Diego Araiza-Garaygordobil, Rodrigo Gopar-Nieto, Pablo Martínez-Amezcua, Alejandro Cabello-Lopez, Daniel Sierra-Lara, José Luis Briseño De La Cruz, Hector Gonzáles Pacheco, Alexandra Arias Mendoza
{"title":"[失代偿性心力衰竭患者 B 型利钠肽 N 端绝对值下降的预后价值:CLUSTER-HF 研究的二次分析】。]","authors":"Cynthia Paredes-Paucar, Leonardo Villa Medina, Diego Araiza-Garaygordobil, Rodrigo Gopar-Nieto, Pablo Martínez-Amezcua, Alejandro Cabello-Lopez, Daniel Sierra-Lara, José Luis Briseño De La Cruz, Hector Gonzáles Pacheco, Alexandra Arias Mendoza","doi":"10.47487/apcyccv.v3i1.198","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study is to determine the prognostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound lung to guide therapy and prevent readmissions in heart failure).</p><p><strong>Materials and methods: </strong>This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the prognostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days.</p><p><strong>Results: </strong>The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a prognostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables.</p><p><strong>Conclusions: </strong>An absolute decrease to 3,350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.</p>","PeriodicalId":72295,"journal":{"name":"Archivos Peruanos de cardiologia y cirugia cardiovascular","volume":"3 1","pages":"8-15"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/86/apcyccv-3-08.PMC10318989.pdf","citationCount":"0","resultStr":"{\"title\":\"[Prognostic value of the absolute decrease of the N-terminal portion of B-type natriuretic propeptide in decompensated heart failure: secondary analysis of the CLUSTER-HF study].\",\"authors\":\"Cynthia Paredes-Paucar, Leonardo Villa Medina, Diego Araiza-Garaygordobil, Rodrigo Gopar-Nieto, Pablo Martínez-Amezcua, Alejandro Cabello-Lopez, Daniel Sierra-Lara, José Luis Briseño De La Cruz, Hector Gonzáles Pacheco, Alexandra Arias Mendoza\",\"doi\":\"10.47487/apcyccv.v3i1.198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The purpose of this study is to determine the prognostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound lung to guide therapy and prevent readmissions in heart failure).</p><p><strong>Materials and methods: </strong>This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the prognostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days.</p><p><strong>Results: </strong>The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a prognostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables.</p><p><strong>Conclusions: </strong>An absolute decrease to 3,350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.</p>\",\"PeriodicalId\":72295,\"journal\":{\"name\":\"Archivos Peruanos de cardiologia y cirugia cardiovascular\",\"volume\":\"3 1\",\"pages\":\"8-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/86/apcyccv-3-08.PMC10318989.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archivos Peruanos de cardiologia y cirugia cardiovascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47487/apcyccv.v3i1.198\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos Peruanos de cardiologia y cirugia cardiovascular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47487/apcyccv.v3i1.198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
[Prognostic value of the absolute decrease of the N-terminal portion of B-type natriuretic propeptide in decompensated heart failure: secondary analysis of the CLUSTER-HF study].
Objective: The purpose of this study is to determine the prognostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound lung to guide therapy and prevent readmissions in heart failure).
Materials and methods: This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the prognostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days.
Results: The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a prognostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables.
Conclusions: An absolute decrease to 3,350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.